TX-AUREA-SOFTWARE-INC
11.1.2022 17:02:08 CET | Business Wire | Press release
Aurea Software Inc. , the “Netflix of business software,” announced Deutsche Telekom is piloting its first-ever Virtual Office using Sococo software from Aurea . Used to better connect its distributed workforce and increase culture and collaboration across the company’s customer service teams, the pilot will run until March.
Deutsche Telekom customer service teams — comprised of 30,000 employees across Germany — are distributed throughout the country. Despite using a geographically distributed and hybrid work setting, team members need to be able to “work as one” to deliver optimal customer experiences.
Using Aurea’s Sococo solution, Deutsche Telekom is at the forefront of solving this problem of connection and culture in the geographically distributed and hybrid workplace by launching a Virtual Office that allows workers to enjoy the same level of connection and presence online that they once enjoyed in person.
“Hybrid work is here to stay. The pandemic started it, but workers embraced it, and there is no going back to a 100 percent in-person work world. And while research supports that working from home has many benefits, it also creates unique challenges,” said Scott Brighton, CEO of Aurea. “Workers can’t connect in the hallways the way they once did. They don’t meet new people on campus or when visiting other offices around the world. Common virtual meeting communication tools have made their work world smaller — encouraging them to stay in regular communication with people they already know, but not empowering them to discover new people or new ideas. This has led to a lack of experiencing a vibrant culture of diversity that was more prominent when workers came into a physical office.”
Brighton added, “With the creation of its Virtual Office, Deutsche Telekom is leading the industry by creating a hybrid-work environment that offers employees more ways to connect, collaborate, and build culture no matter where they are in the world.”
Deutsche Telekom’s Virtual Office looks and feels like an actual office — however, it’s online instead of in a physical building. There are gathering spaces, meeting and conference rooms, and even break areas, giving every employee the ability to see where colleagues are and what they are doing. This creates a rich sense of presence that is missing from basic communication tools that only show a generic status color next to a list of colleagues. Employees can meet and connect with new people using virtual meeting experiences specifically designed to create the casual connections present in in-office settings. For example, Deutsche Telekom’s Virtual Office has a Coffee Roulette room where employees are randomly connected to another co-worker they may not already know. They can spend a few minutes getting to know each other — sharing details about their roles, how they can help each other, and even what inspires them.
Aurea’s Sococo solution is centered around going beyond the basic communication aspects that traditional virtual meeting platforms provide to build true culture and connection.
“Like many large enterprises, Deutsche Telekom thrives, in part, due to the diverse backgrounds and skills of our workforce coming together to share knowledge and collaborate to solve customer issues more efficiently,” said Gereon Hammel, vice president of business development at Deutsche Telekom. “Many of the methods we’ve traditionally relied on to forge this collaboration are lost when functions are shrunk to closed and niche calls with immediate team members. By partnering with Aurea to launch this Virtual Office, we can enable important components of an in-person work environment within our hybrid work setting. This allows us to leverage our scale and diverse workforce, without requiring everyone to be in the same physical office space. The ease at which we can implement the Sococo solution across our team means our Virtual Office can be implemented in a matter of minutes.”
REGISTER TODAY : Hear more from Gereon Hammel and Scott Brighton on how to enable digital connection and build a Virtual Office during VentureBeat’s Future of Work Summit . Sign up today for the January 12 event.
About Aurea:
Aurea helps global businesses accelerate digital transformation through unlimited access to the world’s first business software library, which includes solutions that enable the Future of Commerce, work, and IT. Our customers enjoy access to every product in our portfolio, all of which are cloud-based, enterprise-scale, and easy-to-use with one simple subscription. Our unique operating model and acquisition strategy grows our software portfolio every year, creating unparalleled value and unlimited possibility. For more information, visit Aurea.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005342/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
